Dublin, Dec. 19, 2016 -- Research and Markets has announced the addition of the "Type 1 Diabetes Drugs Price Analysis and Strategies - 2016" report to their offering.
Type 1 Diabetes Drugs Price Analysis and Strategies 2016, provides drug pricing data and benchmarks in the global Type 1 Diabetes market.
The research answers the following questions:
- What are the key drugs marketed for Type 1 Diabetes and their clinical attributes? How are they positioned in the Global Type 1 Diabetes market?
- What are the unit prices and annual treatment cost for Type 1 Diabetes therapies in different countries? What are the drug pricing trends and how are they expected to change in the future? How are the drug pricing and reimbursement landscape different by countries?
- What are the unmet needs in the global Type 1 Diabetes drugs market? What would be the ideal pricing strategy for a new pipeline therapy for Type 1 Diabetes?
Research Scope:
- Treatment Options - Identify key drugs marketed and prescribed for Type 1 Diabetes including trade name, molecule name, and company
- Drugs Attributes - Find out the safety, efficacy, and risk benefit for key drugs marketed for Type 1 Diabetes
- Market Positioning - Identify how drugs are clinically and commercially positioned in the global Type 1 Diabetes market
- Type 1 Diabetes Drugs Price Analysis - Find out the annual therapy cost and unit price for key drugs marketed
- Find out how the price advanced from 2012 and forecast to 2021
- Pricing & Reimbursement Landscape - Find out the pricing and reimbursement landscape
- Type 1 Diabetes New Drug Pricing - Identify the effective pricing strategy for a new drug launch
Key Topics Covered:
1. Treatment Options
2. Drugs Clinical Attributes
3. Drugs Market Positioning
4. Drugs Price Analysis
5. Drugs Price Benchmarks
6. Drug Pricing & Reimbursement Landscape
7. Drugs Price Forecast
8. Market Unmet Needs
9. New Drug Pricing
For more information about this report visit http://www.researchandmarkets.com/research/mxxpkv/type_1_diabetes
CONTACT: Research and Markets
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716
Related Topics: Immune Disorders Drugs, Endocrine and Metabolic Disorder Drugs


7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm
TikTok U.S. Deal Advances as ByteDance Signs Binding Joint Venture Agreement
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Dina Powell McCormick Resigns From Meta Board After Eight Months, May Take Advisory Role
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Oracle Stock Slides After Blue Owl Exit Report, Company Says Michigan Data Center Talks Remain on Track
Elliott Management Takes $1 Billion Stake in Lululemon, Pushes for Leadership Change
Oracle Stock Surges After Hours on TikTok Deal Optimism and OpenAI Fundraising Buzz
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland
Micron Technology Forecasts Surge in Revenue and Earnings on AI-Driven Memory Demand
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 



